Evidence map›Paper›PMID 39026080›Full record

ArticleBritish journal of cancer2024

Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.

Christina M Nagle, Torukiri I Ibiebele, Elisa V Bandera, Daniel Cramer, Jennifer A Doherty, Graham G Giles, Marc T Goodman, Gillian E Hanley, Holly R Harris, Allan Jensen and 16 more

Abstract read
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Christina M NagleGynaecological Cancers Group, Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Torukiri I IbiebeleGynaecological Cancers Group, Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0002-8789-2755
Daniel CramerObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Jennifer A DohertyHuntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Marc T GoodmanCancer Prevention and Control Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Gillian E HanleyUniversity of British Columbia, Department of Obstetrics & Gynaecology, Vancouver, BC, Canada.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark.
Alice W LeeDepartment of Public Health, California State University, Fullerton, Fullerton, CA, USA.ORCID http://orcid.org/0000-0001-8756-7066
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Bo QinCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Jean RichardsonDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Naoko SasamotoObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Weiva SiehDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0085-1190
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Linda TitusDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Britton TrabertMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1539-6090
Nicolas WentzensenClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-1251-0836
Anna H WuDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Andrew BerchuckDivision of Gynecologic Oncology, Duke University School of Medicine, Durham, NC, USA.
Malcolm PikeDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Penelope M WebbGynaecological Cancers Group, Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. penny.webb@qimrberghofer.edu.au.ORCID http://orcid.org/0000-0003-0733-5930

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1985 to 2009
$18.2M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Epidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5M
Steroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3M
ESTROGEN, DIET, GENETICS AND ENDOMETRIAL CANCERR01CA083918 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI OLSON, SARA H · 2001 to 2005
$2.5M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
Phytoestrogens, alcohol, and endometrial cancer riskK07CA095666 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI BANDERA, ELISA V · 2003 to 2007
$672k
Department of Health | National Health and Medical Research Council (NHMRC) 209057, 396414, 1074383NCI NIH HHS K07 CA095666NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA072720NCI NIH HHS P50 CA105009NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA112523NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195Rutgers Cancer Institute of New Jersey (Cancer Institute of New Jersey)United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP) W81XSH-16-2-0010U.S. Department of Defense (United States Department of Defense) W81XWH-10-1-02802U.S. Department of Health & Human Services | National Institutes of Health (NIH) NIH-K07-CA095666, R01-CA83918, NIH-K22-CA138563, P30-CA072720U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, R03-CA113148, R03-CA115195, N01-CN025403U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-CA112523, R01-CA87538U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-CA54419, P50-CA105009U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-CA58598, N01-CN-55424, N01-PC-67001U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-CA61107U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) Intramural Research Program
6 · The paper itself

Abstract

backgroundTea and coffee are the most frequently consumed beverages in the world. Green tea in particular contains compounds with potential anti-cancer effects, but its association with survival after ovarian cancer is uncertain.

methodsWe investigated the associations between tea and coffee consumption before diagnosis and survival using data from 10 studies in the Ovarian Cancer Association Consortium. Data on tea (green, black, herbal), coffee and caffeine intake were available for up to 5724 women. We used Cox proportional hazards regression to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).

resultsCompared with women who did not drink any green tea, consumption of one or more cups/day was associated with better overall survival (aHR = 0.84, 95% CI 0.71-1.00, p-trend = 0.04). A similar association was seen for ovarian cancer-specific survival in five studies with this information (aHR = 0.81, 0.66-0.99, p-trend = 0.045). There was no consistent variation between subgroups defined by clinical or lifestyle characteristics and adjustment for other aspects of lifestyle did not appreciably alter the estimates. We found no evidence of an association between coffee, black or herbal tea, or caffeine intake and survival.

conclusionThe observed association with green tea consumption before diagnosis raises the possibility that consumption after diagnosis might improve patient outcomes.

Indexed as

CoffeeOvarian NeoplasmsTeaAdultAgedCaffeineFemaleHumansMiddle AgedProportional Hazards ModelsCaffeineCoffeeTea

Identifiers

PMID39026080
PMCPMC11405517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.